Raja Banerji | Chief Marketing Officer - Life Sciences, Manufacturing, Energy & Resources
Tata Consultancy Services Limited

Raja Banerji, Chief Marketing Officer - Life Sciences, Manufacturing, Energy & Resources, Tata Consultancy Services Limited

Raja Banerji CHIEF MARKETING OFFICER – BUSINESS GROUP – TATA CONSULTANCY SERVICES I manage and lead Marketing initiatives for three key businesses at Tata Consultancy Services. In this role, I oversee the creation of global marketing campaigns and efficient models that can be replicated across geographies and business units to drive brand awareness and sales opportunities. Key focus areas include the creation of Value messaging, Branding and visibility, driving Thought Leadership with senior management, Digital Transformation Initiatives, sponsorship of events, Analyst and Advisor relations, academic research with premier institutes such as MIT, Harvard, University of Berkeley, Account focused marketing, Public Relations and media. My 25 years of diverse experience includes the spectrum of Insurance & Employee Benefits, Healthcare, Risk Management, Group & Corporate Business, and Government. I have held positions of Sales & General Manager with Metlife, Senior VP with American Healthcare Providers, Managing Director for AON Worksite Solutions, and Senior VP with Marsh and TATA AIG. I have been with the TATA group for ten years, including five years with TCS. An alumni of the Tata Group Executive Leadership program at the Ross School of Business, I have a Masters in International Relations from India and a Masters in International Business from the Patterson School of Diplomacy & International Commerce at University of Kentucky.  


World Drug Safety Europe Day One (Tuesday 12 September ) @ 09:40

Keynote panel: The emergence of new technologies in PV and how to best harness them

  • Developing PV strategies that incorporate social media platforms such as Facebook and Twitter
  • Utilizing mobiles apps for reporting Adverse Drug Reactions
  • Leveraging technology to enhance interactive connection with patients
  • AI and what it could mean for drug safety

back to speakers